Capsida Biotherapeutics Enters Strategic Collaboration With Kate Therapeutics
03 Oct 2023 //
PR NEWSWIRE
Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430
08 Jun 2023 //
PR NEWSWIRE
Kate Therapeutics Debuts With $51 Million Series A to Develop Genetic Medicines
08 Jun 2023 //
PR NEWSWIRE